8:30 am  **WELCOME AND INTRODUCTION**  Dr. M. Moore

8:40 am  **COLON DISEASE ORIENTED WORKING GROUP**  Dr. D. Jonker, Dr. S. Gill

**CLOSED TRIALS**

**CO.17:** A Phase III Randomized Study of Cetuximab (Erbitux™, C225) and Best Supportive Care versus Best Supportive Care in Patients with Pretreated Metastatic Epidermal Growth Factor Receptor (EGFR)-Positive Colorectal Carcinoma

- Main Trial Results  Dr. D. Jonker
- Quality of Life Analyses  Dr. H.J. Au
- Proposed Economic Analyses  Dr. H.J. Au / Dr. N. Mittman

**ENDORSED CTSU TRIALS**

**CRC.2** (NCCTG N0147): A Randomized Phase III Trial of Irinotecan (CPT-11) and/or Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) with or without Cetuximab (C225) after Curative Resection for Patients with Stage III Colon Cancer  Dr. S. Gill

**CRC.3** (ECOG E5202): A Randomized Phase III Study Comparing 5-FU Leucovorin and Oxaliplatin versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers.  Dr. C. Butts

**APPROVED TRIALS IN DEVELOPMENT**

**IND.171:** A Phase I, Open-Label, Dose-Seeking Study of AZD2171 Given Daily Orally in Combination with Selected Standard Chemotherapy Regimens (CT) in Patients with Advanced Incurable Non-Small Cell Lung Cancer (NSCLC) or Colorectal Cancer  Dr. D. Jonker

**CO.18:** A Phase II Study of AZD2171 and Capecitabine versus Capecitabine Alone as 1st Line Therapy in Patients with Metastatic Colorectal Cancer  Dr. C. Cripps
**APPROVED TRIALS IN DEVELOPMENT (CONTINUED)**

**CO.20**: A Phase III Randomized Study of BMS582664 and Cetuximab (ErbituxTM) versus Cetuximab in Patients with Pretreated Metastatic Colorectal Carcinoma

10:15 am **REFRESHMENT BREAK**

10:30 am **COLON DISEASE ORIENTED WORKING GROUP (CONTINUED)**

**NEW TRIALS / CONCEPTS / PROPOSALS**

TBA

11:00 am **NEUROENDOCRINE TUMOUR DISEASE ORIENTED WORKING GROUP**

**NEW TRIALS / CONCEPTS / PROPOSALS**

TBA

11:20 am **RECTAL DISEASE ORIENTED WORKING GROUP**

**ENDORSED CTSU TRIALS**

**CRC.4** (ECOG E5204): Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil and Leucovorin vs Oxaliplatin, 5-Fluorouracil, Leucovorin and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Pre-operative Chemoradiation.

11:50 am **IND REPORT**

12:00 pm **LUNCH**

1:00 pm **ESOPHAGEAL DISEASE ORIENTED WORKING GROUP**

**ACTIVE TRIALS**

**ES.2** (TROG 03.01): A Randomised Phase III Study in Advanced Oesophageal Cancer to Compare Quality of Life and palliation of Dysphagia in Patients Treated with Radiotherapy versus Chemo-Radiotherapy

Dr. L. Siu

Dr. D. Jonker, Dr. S. Gill

Dr. L. Siu, Dr. W. Kocha

Dr. J. Brierley, Dr. N. Baxter

Dr. J. Brierely

Dr. J. Brierley, Dr. N. Baxter

Dr. J. Brierley

Dr. J. Brierley

Dr. Ralph Wong

Dr. Rebecca Wong, Dr. C. Kollmannsberger

Dr. Rebecca Wong
1:00 pm  **ESOPHAGEAL DISEASE ORIENTED WORKING GROUP (CONTINUED)**

**ENDORSED CTSU TRIALS**

**GAC.1 (CALGB-80101):** A Phase III Trial of Adjuvant Chemoradiation After Resection of Gastric Or Gastroesophageal Adenocarcinoma  
Dr. G. Bjarnason

**NEW TRIALS / CONCEPTS / PROPOSALS**

TBA

2:00 pm  **PANCREATIC DISEASE ORIENTED WORKING GROUP**  
Dr. M. Moore, Dr. S. Gallinger

**CLOSED TRIALS**

**PAC.1 (SWOG-S0205):** A Randomized Placebo Controlled Study of Cetuximab plus Gemcitabine in Patients with Locally Advanced, Unresectable or Metastatic Pancreatic Cancer  
Dr. Ralph Wong

**ACTIVE TRIALS**

**PA.2 (ESPAC-3):** Adjuvant Chemotherapies in Resectable Pancreatic Cancer  
Dr. M. Moore

**NEW TRIALS / CONCEPTS / PROPOSALS**

TBA

2:45 pm  **HEPATOBILIARY DISEASE ORIENTED WORKING GROUP**  
Dr. J. Knox, Dr. O. Bathe

**APPROVED TRIALS IN DEVELOPMENT**

**BI.1:** A Phase III Study of Gemcitabine Plus Capecitabine (GEMCAP) versus Gemcitabine Alone in Advanced Biliary Cancer  
Dr. J. Knox

**NEW TRIALS / CONCEPTS / PROPOSALS**

TBA

3:15 pm  **CLOSING REMARKS & ADJOURNMENT**  
Dr. M. Moore

3:30 pm  **CLOSED SESSION: GI EXECUTIVE MEETING**  
Dr. M. Moore